Study S000023

SGLT2 INHIBITION AND STIMULATION OF ENDOGENOUS GLUCOSE PRODUCTION [EGP]: Can the Glucagon-like Peptide-1 [GLP-1] Receptor Agonist, Exenatide, Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT03331289
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 107
Start: 2018-02-28
Primary completion: 2022-03-31
Lead sponsor: The University of Texas Health Science Center at San Antonio
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Placebo; DRUG:Exenatide; DRUG:Dapagliflozin; DRUG:Exenatide and Dapagliflozin
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: NIH:R01DK107680

Registered primary outcomes

Change in EGP From Baseline to Post-oral Glucose Load. [From baseline [-35 to 0min] to the last hour post-glucose load [240-300 minutes]]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0026789	Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose. Alatrach M, Diabetes care	2022	Other	PMID 35235659 DOI	cites ClinicalTrials.gov:NCT03331289; registry reference DERIVED:35235659